MedTrace Logo

A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer

NCT05361902 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-08-28

No results posted yet for this study

Summary

This study aims to make a first step towards ultra-hypofractionation for high-risk prostate cancer by proving the technical feasibility of margin reduction of the seminal vesicles by combining the intra-fraction fiducial tracking with an online re-planning workflow for each fraction to account for the inter-fraction seminal vesicle motion.

Conditions

Interventions

RADIATION

Adaptive radiotherapy according to UPRATE protocol

According to previously reported STAMPEDE trial (Parker et al.), patients will be treated with 6 weekly fractions of 6 Gy. According to local protocol the target will consist of prostate and entire seminal vesicles. Additional CT-scans will be made prior to and directly following each fraction. For more details, see study description

Sponsors & Collaborators

Principal Investigators

  • Luca Incrocci, Professor · Erasmus Medical Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-07
Primary Completion
2024-06-13
Completion
2027-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05361902 on ClinicalTrials.gov